SCHEMBL6292707

SCHEMBL6292707

CC(=NO)C(=NOc1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 3/20 0.34
HPGD P15428 2/20 0.34
POLB P06746 1/20 0.34
XBP1 P17861 1/20 0.34
MAOB P27338 2/20 0.34
PKM P14618 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
ELANE P08246 1/20 0.33
RAB9A P51151 4/20 0.33
NPC1 O15118 3/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296504 0.86 GAA (0.43) GAACYP2C19L3MBTL1LMNAMAPK1
SCHEMBL8460844 0.81 GAA (0.41) GAACYP2C19L3MBTL1LMNAMAPK1
SCHEMBL5597826 0.81 GAA (0.41) GAACYP2C19L3MBTL1LMNAMAPK1
SCHEMBL5265637 0.78 GAA (0.54) GAACYP2C19L3MBTL1LMNAMAPK1
SCHEMBL5265634 0.78 GAA (0.54) GAACYP2C19L3MBTL1LMNAMAPK1
SCHEMBL11539714 0.76 CYP2C19 (0.42) GAACYP2C19L3MBTL1LMNAALDH1A1
SCHEMBL11539712 0.76 CYP2C19 (0.42) GAACYP2C19L3MBTL1LMNAALDH1A1
SCHEMBL4875607 0.73 GAA (0.35) GAACYP2C19
SCHEMBL7760451 0.73 GAA (0.48) GAACYP2C19L3MBTL1LMNAMAPK1
SCHEMBL7760450 0.73 GAA (0.48) GAACYP2C19L3MBTL1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858745-B2 Alkyl cobalt (III) dioximates and process for forming the same E. I. DU PONT DE NEMOURS AND COMPANY (US) 2005-02-22 US disclosed
US-6740618-B2 REACTIN A GLYOXIME, A COBALT SALT, AN UNSATURATED COMPOUND SUCH AS AN ALKYL ACRYLATE, AND A LEWIS BASE IN H2; USE AS A POLYMERIZATION CATALYST, ESPECIALLY IN POLYMERIZING METHYL METHACRYLATE E. I. DU PONT DE NEMOURS AND COMPANY 2004-05-25 US disclosed
US-6713427-B2 TREATING A MIXTURE OF A COBALT (II) SALT, A DIOXIME OF THE FORMULA R1-C( HORIZONTAL-LINE NOH)-C( HORIZONTAL-LINE NOH)-R2, AN ACRYLIC ESTER, A LEWIS BASE WITH MOLECULAR HYDROGEN TO FORM A COBALT DIOXIMATE COMPLEX E. I. DU PONT DE NEMOURS AND COMPANY 2004-03-30 US disclosed
US-20030149275-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2003-08-07 US disclosed
US-20030135054-A1 Alkyl cobalt(III) dioximates and process for forming the same GRIDNEV ALEXEI A (US) 2003-07-17 US disclosed
US-20030125564-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2003-07-03 US disclosed
US-6559327-B2 By reacting a cobalt salt, a dioxime such as diphenylglyoxime, a lewis base such as 1,2-dimethylimidazole, and an olefinic compound such as methyl acrylate, and treating with hydrogen; high yield, purity E. I. DU PONT DE NEMOURS AND COMPANY 2003-05-06 US disclosed
EP-1221447-A2 Alkyl Cobalt (III) Dioximates and process for forming the same E. I. du Pont de Nemours and Company (US) 2002-07-10 EP disclosed
US-20020087006-A1 Alkyl cobalt (III) dioximates and process for forming the same AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149275-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4343/4885CYP2C19 2755/4885L3MBTL1 2127/4885
US-20030125564-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4331/4885CYP2C19 2760/4885L3MBTL1 2106/4885
US-20020087006-A1 Alkyl cobalt (III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4331/4885CYP2C19 2760/4885L3MBTL1 2106/4885
US-20030135054-A1 Alkyl cobalt(III) dioximates and process for forming the same CCR3, CBR3, CCR6 GAA 4331/4885CYP2C19 2760/4885L3MBTL1 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.